Edwards Lifesciences Corporation (NYSE: EW) Stock Competitors & Peer Comparison

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, ABT has a market cap of 179.1B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while ABT trades at $103.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas ABT's P/E ratio is 19.87. In terms of profitability, EW's ROE is +0.10%, compared to ABT's ROE of +0.11%. Regarding short-term risk, EW is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for EW.Check ABT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, EW's ROE is +0.10%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, EW is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for EW.Check BSX-PA's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, MDT has a market cap of 114.3B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while MDT trades at $89.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas MDT's P/E ratio is 16.15. In terms of profitability, EW's ROE is +0.10%, compared to MDT's ROE of +0.11%. Regarding short-term risk, EW is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for EW.Check MDT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, SYK has a market cap of 104.8B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while SYK trades at $273.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas SYK's P/E ratio is 20.42. In terms of profitability, EW's ROE is +0.10%, compared to SYK's ROE of +0.16%. Regarding short-term risk, EW is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for EW.Check SYK's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, BSX has a market cap of 66.4B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while BSX trades at $44.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas BSX's P/E ratio is 14.40. In terms of profitability, EW's ROE is +0.10%, compared to BSX's ROE of +0.15%. Regarding short-term risk, EW is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for EW.Check BSX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, DXCM has a market cap of 33.1B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while DXCM trades at $87.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas DXCM's P/E ratio is 34.40. In terms of profitability, EW's ROE is +0.10%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, EW is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for EW.Check DXCM's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, GEHC has a market cap of 29.9B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while GEHC trades at $66.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas GEHC's P/E ratio is 14.49. In terms of profitability, EW's ROE is +0.10%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, EW is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for EW.Check GEHC's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, PHG has a market cap of 23.9B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while PHG trades at $24.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas PHG's P/E ratio is 13.97. In terms of profitability, EW's ROE is +0.10%, compared to PHG's ROE of +0.10%. Regarding short-term risk, EW is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for EW.Check PHG's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, ZBH has a market cap of 17.6B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while ZBH trades at $90.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas ZBH's P/E ratio is 10.72. In terms of profitability, EW's ROE is +0.10%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, EW is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for EW.Check ZBH's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas ABMD's P/E ratio is 65.36. In terms of profitability, EW's ROE is +0.10%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, EW is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for EW.Check ABMD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while PEN trades at $319.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas PEN's P/E ratio is 83.37. In terms of profitability, EW's ROE is +0.10%, compared to PEN's ROE of +0.11%. Regarding short-term risk, EW is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for EW.Check PEN's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas SWAV's P/E ratio is 78.76. In terms of profitability, EW's ROE is +0.10%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, EW is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for EW.Check SWAV's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, SNN has a market cap of 11.3B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while SNN trades at $26.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas SNN's P/E ratio is 18.10. In terms of profitability, EW's ROE is +0.10%, compared to SNN's ROE of +0.12%. Regarding short-term risk, EW is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for EW.Check SNN's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, ALGN has a market cap of 10.6B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while ALGN trades at $148.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas ALGN's P/E ratio is 13.51. In terms of profitability, EW's ROE is +0.10%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, EW is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for EW.Check ALGN's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, BIO-B has a market cap of 10.3B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while BIO-B trades at $374.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas BIO-B's P/E ratio is -65.99. In terms of profitability, EW's ROE is +0.10%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, EW is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for EW.Check BIO-B's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while BIO trades at $378.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas BIO's P/E ratio is 40.83. In terms of profitability, EW's ROE is +0.10%, compared to BIO's ROE of +0.03%. Regarding short-term risk, EW is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for EW.Check BIO's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, GMED has a market cap of 10B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while GMED trades at $73.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas GMED's P/E ratio is 16.66. In terms of profitability, EW's ROE is +0.10%, compared to GMED's ROE of +0.12%. Regarding short-term risk, EW is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for EW.Check GMED's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, PODD has a market cap of 9.5B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while PODD trades at $136.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas PODD's P/E ratio is 23.25. In terms of profitability, EW's ROE is +0.10%, compared to PODD's ROE of +0.27%. Regarding short-term risk, EW is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for EW.Check PODD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas MASI's P/E ratio is 44.43. In terms of profitability, EW's ROE is +0.10%, compared to MASI's ROE of +0.09%. Regarding short-term risk, EW is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for EW.Check MASI's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, BRKR has a market cap of 9.1B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while BRKR trades at $59.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas BRKR's P/E ratio is 29.98. In terms of profitability, EW's ROE is +0.10%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, EW is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for EW.Check BRKR's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, GKOS has a market cap of 9.1B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while GKOS trades at $153.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas GKOS's P/E ratio is -178.48. In terms of profitability, EW's ROE is +0.10%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, EW is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for EW.Check GKOS's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, BRKRP has a market cap of 8.8B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while BRKRP trades at $439.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas BRKRP's P/E ratio is 238.95. In terms of profitability, EW's ROE is +0.10%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, EW is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for EW.Check BRKRP's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, HAE has a market cap of 4.9B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while HAE trades at $106.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas HAE's P/E ratio is 21.32. In terms of profitability, EW's ROE is +0.10%, compared to HAE's ROE of +0.11%. Regarding short-term risk, EW is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for EW.Check HAE's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas NARI's P/E ratio is -59.24. In terms of profitability, EW's ROE is +0.10%, compared to NARI's ROE of -0.00%. Regarding short-term risk, EW is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for EW.Check NARI's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while ITGR trades at $126.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas ITGR's P/E ratio is 19.89. In terms of profitability, EW's ROE is +0.10%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, EW is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for EW.Check ITGR's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while LIVN trades at $77.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas LIVN's P/E ratio is 18.33. In terms of profitability, EW's ROE is +0.10%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, EW is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for EW.Check LIVN's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while IRTC trades at $111.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas IRTC's P/E ratio is -259.88. In terms of profitability, EW's ROE is +0.10%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, EW is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for EW.Check IRTC's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas AXNX's P/E ratio is -709.80. In terms of profitability, EW's ROE is +0.10%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, EW is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for EW.Check AXNX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, TMDX has a market cap of 3B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while TMDX trades at $87.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas TMDX's P/E ratio is 44.16. In terms of profitability, EW's ROE is +0.10%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, EW is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for EW.Check TMDX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, NEOG has a market cap of 3B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while NEOG trades at $13.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas NEOG's P/E ratio is 48.46. In terms of profitability, EW's ROE is +0.10%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, EW is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for EW.Check NEOG's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while BFLY trades at $9.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas BFLY's P/E ratio is -38.31. In terms of profitability, EW's ROE is +0.10%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, EW is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for EW.Check BFLY's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while AXGN trades at $43.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas AXGN's P/E ratio is 114.00. In terms of profitability, EW's ROE is +0.10%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, EW is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for EW.Check AXGN's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, UFPT has a market cap of 2.2B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while UFPT trades at $287.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas UFPT's P/E ratio is 29.35. In terms of profitability, EW's ROE is +0.10%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, EW is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for EW.Check UFPT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas NUVA's P/E ratio is 75.00. In terms of profitability, EW's ROE is +0.10%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, EW is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for EW.Check NUVA's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, INSP has a market cap of 2B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while INSP trades at $69.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas INSP's P/E ratio is 30.41. In terms of profitability, EW's ROE is +0.10%, compared to INSP's ROE of +0.18%. Regarding short-term risk, EW is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for EW.Check INSP's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, ESTA has a market cap of 2B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while ESTA trades at $67.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas ESTA's P/E ratio is -53.78. In terms of profitability, EW's ROE is +0.10%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, EW is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for EW.Check ESTA's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while NVCR trades at $16.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas NVCR's P/E ratio is -12.50. In terms of profitability, EW's ROE is +0.10%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, EW is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for EW.Check NVCR's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while ATEC trades at $10.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas ATEC's P/E ratio is -167.17. In terms of profitability, EW's ROE is +0.10%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, EW is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for EW.Check ATEC's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while CNMD trades at $45.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas CNMD's P/E ratio is 10.07. In terms of profitability, EW's ROE is +0.10%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, EW is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for EW.Check CNMD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas HSKA's P/E ratio is -62.49. In terms of profitability, EW's ROE is +0.10%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, EW is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for EW.Check HSKA's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, IART has a market cap of 1.2B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while IART trades at $15.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas IART's P/E ratio is 6.58. In terms of profitability, EW's ROE is +0.10%, compared to IART's ROE of -0.01%. Regarding short-term risk, EW is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for EW.Check IART's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas AVNS's P/E ratio is 27.77. In terms of profitability, EW's ROE is +0.10%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, EW is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for EW.Check AVNS's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while AORT trades at $23.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas AORT's P/E ratio is 39.20. In terms of profitability, EW's ROE is +0.10%, compared to AORT's ROE of -0.01%. Regarding short-term risk, EW is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for EW.Check AORT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while TNDM trades at $16.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas TNDM's P/E ratio is -17.61. In terms of profitability, EW's ROE is +0.10%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, EW is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for EW.Check TNDM's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas SILK's P/E ratio is -18.96. In terms of profitability, EW's ROE is +0.10%, compared to SILK's ROE of -0.35%. Regarding short-term risk, EW is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for EW.Check SILK's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while IRMD trades at $86.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas IRMD's P/E ratio is 43.39. In terms of profitability, EW's ROE is +0.10%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, EW is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for EW.Check IRMD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas FNA's P/E ratio is -19.83. In terms of profitability, EW's ROE is +0.10%, compared to FNA's ROE of -0.35%. Regarding short-term risk, EW is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for EW.Check FNA's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, ENOV has a market cap of 1B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while ENOV trades at $18.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas ENOV's P/E ratio is 5.22. In terms of profitability, EW's ROE is +0.10%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, EW is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for EW.Check ENOV's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, PRCT has a market cap of 1B. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while PRCT trades at $18.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas PRCT's P/E ratio is -9.32. In terms of profitability, EW's ROE is +0.10%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, EW is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for EW.Check PRCT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, BBNX has a market cap of 998.3M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while BBNX trades at $22.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas BBNX's P/E ratio is -13.45. In terms of profitability, EW's ROE is +0.10%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, EW is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for EW.Check BBNX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, LMRI has a market cap of 974.3M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while LMRI trades at $10.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas LMRI's P/E ratio is -19.73. In terms of profitability, EW's ROE is +0.10%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, EW is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for EW.Check LMRI's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, BVS has a market cap of 922.1M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while BVS trades at $13.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas BVS's P/E ratio is 17.91. In terms of profitability, EW's ROE is +0.10%, compared to BVS's ROE of +0.28%. Regarding short-term risk, EW is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for EW.Check BVS's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, CBLL has a market cap of 896.2M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while CBLL trades at $23.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas CBLL's P/E ratio is -13.42. In terms of profitability, EW's ROE is +0.10%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, EW is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for EW.Check CBLL's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas CSII's P/E ratio is -20.83. In terms of profitability, EW's ROE is +0.10%, compared to CSII's ROE of -0.14%. Regarding short-term risk, EW is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for EW.Check CSII's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, SIBN has a market cap of 824.9M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while SIBN trades at $18.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas SIBN's P/E ratio is -54.71. In terms of profitability, EW's ROE is +0.10%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, EW is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for EW.Check SIBN's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, INMD has a market cap of 815.7M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while INMD trades at $14.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas INMD's P/E ratio is 9.85. In terms of profitability, EW's ROE is +0.10%, compared to INMD's ROE of +0.12%. Regarding short-term risk, EW is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for EW.Check INMD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, VREX has a market cap of 776.7M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while VREX trades at $18.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas VREX's P/E ratio is 19.42. In terms of profitability, EW's ROE is +0.10%, compared to VREX's ROE of +0.05%. Regarding short-term risk, EW is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for EW.Check VREX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, AHCO has a market cap of 775.5M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while AHCO trades at $5.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas AHCO's P/E ratio is 11.63. In terms of profitability, EW's ROE is +0.10%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, EW is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for EW.Check AHCO's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, AVR has a market cap of 740.9M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while AVR trades at $7.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas AVR's P/E ratio is -3.93. In terms of profitability, EW's ROE is +0.10%, compared to AVR's ROE of -0.78%. Regarding short-term risk, EW is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for EW.Check AVR's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, CTKB has a market cap of 733.5M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while CTKB trades at $5.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas CTKB's P/E ratio is -30.09. In terms of profitability, EW's ROE is +0.10%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, EW is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for EW.Check CTKB's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, SSII has a market cap of 622.4M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while SSII trades at $3.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas SSII's P/E ratio is -51.83. In terms of profitability, EW's ROE is +0.10%, compared to SSII's ROE of -0.27%. Regarding short-term risk, EW is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for EW.Check SSII's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas SRDX's P/E ratio is -34.66. In terms of profitability, EW's ROE is +0.10%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, EW is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for EW.Check SRDX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas APEN's P/E ratio is -9.43. In terms of profitability, EW's ROE is +0.10%, compared to APEN's ROE of -0.85%. Regarding short-term risk, EW is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for EW.Check APEN's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, KIDS has a market cap of 573.5M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while KIDS trades at $22.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas KIDS's P/E ratio is -18.92. In terms of profitability, EW's ROE is +0.10%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, EW is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for EW.Check KIDS's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, DCTH has a market cap of 551M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while DCTH trades at $15.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas DCTH's P/E ratio is 1596.00. In terms of profitability, EW's ROE is +0.10%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, EW is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for EW.Check DCTH's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, EW's ROE is +0.10%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, EW is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for EW.Check ZIMV's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, CERS has a market cap of 524M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while CERS trades at $2.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas CERS's P/E ratio is -86.38. In terms of profitability, EW's ROE is +0.10%, compared to CERS's ROE of -0.10%. Regarding short-term risk, EW is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for EW.Check CERS's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, TCMD has a market cap of 505.9M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while TCMD trades at $22.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas TCMD's P/E ratio is 20.77. In terms of profitability, EW's ROE is +0.10%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, EW is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for EW.Check TCMD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, NPCE has a market cap of 484.5M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while NPCE trades at $14.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas NPCE's P/E ratio is -24.93. In terms of profitability, EW's ROE is +0.10%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, EW is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for EW.Check NPCE's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, SGHT has a market cap of 462.5M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while SGHT trades at $8.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas SGHT's P/E ratio is -15.18. In terms of profitability, EW's ROE is +0.10%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, EW is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for EW.Check SGHT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, CLPT has a market cap of 448.9M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while CLPT trades at $14.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas CLPT's P/E ratio is -12.69. In terms of profitability, EW's ROE is +0.10%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, EW is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for EW.Check CLPT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, PACB has a market cap of 437.9M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while PACB trades at $1.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas PACB's P/E ratio is -3.44. In terms of profitability, EW's ROE is +0.10%, compared to PACB's ROE of -49.62%. Regarding short-term risk, EW is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for EW.Check PACB's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, SENS has a market cap of 416.9M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while SENS trades at $9.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas SENS's P/E ratio is -4.47. In terms of profitability, EW's ROE is +0.10%, compared to SENS's ROE of -1.66%. Regarding short-term risk, EW is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for EW.Check SENS's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, OFIX has a market cap of 371.1M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while OFIX trades at $9.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas OFIX's P/E ratio is -5.98. In terms of profitability, EW's ROE is +0.10%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, EW is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for EW.Check OFIX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas SMLR's P/E ratio is 3.92. In terms of profitability, EW's ROE is +0.10%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, EW is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for EW.Check SMLR's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, TLSI has a market cap of 307.9M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while TLSI trades at $5.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas TLSI's P/E ratio is -2.98. In terms of profitability, EW's ROE is +0.10%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, EW is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for EW.Check TLSI's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, CV has a market cap of 302.3M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while CV trades at $6.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas CV's P/E ratio is -9.60. In terms of profitability, EW's ROE is +0.10%, compared to CV's ROE of -1.78%. Regarding short-term risk, EW is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for EW.Check CV's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, CATX has a market cap of 298.4M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while CATX trades at $2.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas CATX's P/E ratio is -1.97. In terms of profitability, EW's ROE is +0.10%, compared to CATX's ROE of -0.42%. Regarding short-term risk, EW is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for EW.Check CATX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, TMCI has a market cap of 292.6M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while TMCI trades at $4.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas TMCI's P/E ratio is -4.80. In terms of profitability, EW's ROE is +0.10%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, EW is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for EW.Check TMCI's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, RCEL has a market cap of 272M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while RCEL trades at $10.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas RCEL's P/E ratio is -7.60. In terms of profitability, EW's ROE is +0.10%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, EW is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for EW.Check RCEL's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, INFU has a market cap of 257.5M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while INFU trades at $12.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas INFU's P/E ratio is 31.12. In terms of profitability, EW's ROE is +0.10%, compared to INFU's ROE of +0.15%. Regarding short-term risk, EW is similarly volatile compared to INFU. This indicates similar risk in terms of short-term price fluctuations for EW.Check INFU's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas MGRM's P/E ratio is -12.00. In terms of profitability, EW's ROE is +0.10%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, EW is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for EW.Check MGRM's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, ELMD has a market cap of 229.8M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while ELMD trades at $27.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas ELMD's P/E ratio is 21.18. In terms of profitability, EW's ROE is +0.10%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, EW is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for EW.Check ELMD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas NVRO's P/E ratio is -1.91. In terms of profitability, EW's ROE is +0.10%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, EW is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for EW.Check NVRO's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, PROF has a market cap of 208.4M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while PROF trades at $5.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas PROF's P/E ratio is -5.85. In terms of profitability, EW's ROE is +0.10%, compared to PROF's ROE of -0.56%. Regarding short-term risk, EW is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for EW.Check PROF's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, RXST has a market cap of 200.8M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while RXST trades at $4.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas RXST's P/E ratio is -4.29. In terms of profitability, EW's ROE is +0.10%, compared to RXST's ROE of -0.17%. Regarding short-term risk, EW is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for EW.Check RXST's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, STIM has a market cap of 200.4M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while STIM trades at $2.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas STIM's P/E ratio is -6.55. In terms of profitability, EW's ROE is +0.10%, compared to STIM's ROE of -1.51%. Regarding short-term risk, EW is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for EW.Check STIM's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas BSGM's P/E ratio is -5.81. In terms of profitability, EW's ROE is +0.10%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, EW is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for EW.Check BSGM's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas MDGS's P/E ratio is -0.27. In terms of profitability, EW's ROE is +0.10%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, EW is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for EW.Check MDGS's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, FOCL has a market cap of 177.7M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while FOCL trades at $4.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas FOCL's P/E ratio is -4.58. In terms of profitability, EW's ROE is +0.10%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, EW is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for EW.Check FOCL's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas QIPT's P/E ratio is -15.87. In terms of profitability, EW's ROE is +0.10%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, EW is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for EW.Check QIPT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, LUCD has a market cap of 160M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while LUCD trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas LUCD's P/E ratio is -2.27. In terms of profitability, EW's ROE is +0.10%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, EW is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for EW.Check LUCD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, QSI has a market cap of 150.1M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while QSI trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas QSI's P/E ratio is -1.65. In terms of profitability, EW's ROE is +0.10%, compared to QSI's ROE of -0.47%. Regarding short-term risk, EW is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for EW.Check QSI's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, QTRX has a market cap of 148.9M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while QTRX trades at $3.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas QTRX's P/E ratio is -1.24. In terms of profitability, EW's ROE is +0.10%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, EW is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for EW.Check QTRX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, INGN has a market cap of 137.8M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while INGN trades at $5.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas INGN's P/E ratio is -5.59. In terms of profitability, EW's ROE is +0.10%, compared to INGN's ROE of -0.13%. Regarding short-term risk, EW is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for EW.Check INGN's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas ICAD's P/E ratio is -20.37. In terms of profitability, EW's ROE is +0.10%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, EW is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for EW.Check ICAD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, ECOR has a market cap of 103M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while ECOR trades at $11.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas ECOR's P/E ratio is -6.80. In terms of profitability, EW's ROE is +0.10%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, EW is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for EW.Check ECOR's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas HJLI's P/E ratio is N/A. In terms of profitability, EW's ROE is +0.10%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, EW is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for EW.Check HJLI's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 50B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, EW is priced at $86.82 on the NYSE, while ASXC trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 32.15, whereas ASXC's P/E ratio is -1.12. In terms of profitability, EW's ROE is +0.10%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, EW is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for EW.Check ASXC's competition here